MDT-AP-0531
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 10.44
- os_event
- true
- age_years
- 3.74
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.320471368
- umap2_2d
- -0.272262183
- umap1_3d
- -1.071241536
- umap2_3d
- -2.710676343
- umap3_3d
- -0.80577485
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MYC_TARGETS_V1+0.310
- WNT_BETA_CATENIN_SIGNALING+0.300
- DNA_REPAIR+0.230
- TGF_BETA_SIGNALING+0.200
- E2F_TARGETS+0.190
- OXIDATIVE_PHOSPHORYLATION+0.170
- KRAS_SIGNALING_DN+0.150
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.140
- NOTCH_SIGNALING+0.140
Top 10 suppressed
- PROTEIN_SECRETION-0.320
- HEDGEHOG_SIGNALING-0.230
- INTERFERON_GAMMA_RESPONSE-0.230
- MITOTIC_SPINDLE-0.230
- ANDROGEN_RESPONSE-0.220
- INTERFERON_ALPHA_RESPONSE-0.190
- UV_RESPONSE_DN-0.190
- KRAS_SIGNALING_UP-0.160
- HEME_METABOLISM-0.150
- XENOBIOTIC_METABOLISM-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_K81DR8XG | medulloblastoma | — | 0.735 |
| 2 | d7856acd-b750-4d86-988f-371045e74768 | — | — | 0.728 |
| 3 | TCGA-E2-A2P5-01A-11R-A19W-07 | — | B | 0.691 |
| 4 | 5f537d3b-4d1f-4e68-9bd2-807042bda531 | — | — | 0.687 |
| 5 | MNG437 | — | — | 0.676 |
| 6 | MDT-AP-0761 | Med | Medulloblastoma | 0.662 |
| 7 | MDT-AP-0845 | Med | Medulloblastoma | 0.659 |
| 8 | TCGA-B6-A409-01A-11R-A24H-07 | — | E | 0.658 |
| 9 | MDT-AP-2382 | Med | Medulloblastoma | 0.652 |
| 10 | e5bfa150-ea77-423d-b26c-62f9b241e2b7 | — | — | 0.650 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |